Liora Biosciences accelerates breakthroughs in molecular imaging and theranostics by building the next generation of purpose-built clinical trial sites. Traditional research sites weren’t designed for theranostics and dosimetry studies. Activation delays of 6-12 months or more, fragmented vendor handoffs, and limited nuclear medicine & nuclear oncology expertise slow the development of promising therapies — costing sponsors valuable time and patients' critical access to innovation. Liora Biosciences was created to change that.

Our flagship facility, Florida Theranostics (FLT ), is engineered for advanced molecular imaging and early-phase clinical trials. Equipped with state of the art digital PET/CT and SPECT/CT systems, full dosimetry capabilities, and radiopharmaceutical handling infrastructure, it delivers what conventional sites cannot: speed, precision, expertise, and confidence. At Liora Biosciences, we don’t just participate in trials—we accelerate them. Our integrated model combines imaging, regulatory, and operational expertise under one roof. Our integrated model facilitates fast tracking processes and rapid trial activation. Our model reduces costly delays, supports regulatory alignment, and provides sponsors with cleaner data and faster first-patient-in (FPI) milestones. As the demand for targeted radionuclide therapies grows, Liora Biosciences offers a turnkey solution with an imaging-and dosimetry ready theranostics site — built to accelerate oncology and precision medicine trials in the U.S.

Connect with us to explore trial partnerships and site opportunities, email info@liorabios.com.

Liora Biosciences

Org chart

Teams

Offices